Connexin43 Containing Gap Junction Channels Facilitate HIV Bystander Toxicity: Implications in NeuroHIV
暂无分享,去创建一个
[1] E. Eugenin,et al. Role of Connexin and Pannexin containing channels in HIV infection and NeuroAIDS , 2017, Neuroscience Letters.
[2] A. Nath,et al. Astrocytes as an HIV Reservoir: Mechanism of HIV Infection. , 2016, Current HIV research.
[3] E. Eugenin,et al. Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems. , 2016, Current HIV research.
[4] V. Valcour,et al. Cognitive Impairment and Persistent CNS Injury in Treated HIV , 2016, Current HIV/AIDS Reports.
[5] M. Bennett,et al. HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS , 2016, Journal of Neuroinflammation.
[6] P. Ferdinandy,et al. Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. , 2015, Pharmacology & therapeutics.
[7] Xue-li Yu,et al. Connexin 43 stabilizes astrocytes in a stroke-like milieu to facilitate neuronal recovery , 2015, Acta Pharmacologica Sinica.
[8] V. Bond,et al. Association of Cytokines With Exosomes in the Plasma of HIV-1-Seropositive Individuals. , 2015, The Journal of infectious diseases.
[9] Nathalie Rouach,et al. Astroglial connexin 43 sustains glutamatergic synaptic efficacy , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[10] M. Bennett,et al. HIV increases the release of dickkopf‐1 protein from human astrocytes by a Cx43 hemichannel‐dependent mechanism , 2014, Journal of neurochemistry.
[11] Wang Xi,et al. Astrocyte‐restricted disruption of connexin‐43 impairs neuronal plasticity in mouse barrel cortex , 2014, The European journal of neuroscience.
[12] J. Berman,et al. Cytochrome c dysregulation induced by HIV infection of astrocytes results in bystander apoptosis of uninfected astrocytes by an IP3 and calcium‐dependent mechanism , 2013, Journal of neurochemistry.
[13] Wei Zhang,et al. Biochemical and Biologic Characterization of Exosomes and Microvesicles as Facilitators of HIV-1 Infection in Macrophages , 2012, The Journal of Immunology.
[14] M. Bennett,et al. The Role of Gap Junction Channels During Physiologic and Pathologic Conditions of the Human Central Nervous System , 2012, Journal of Neuroimmune Pharmacology.
[15] J. Clements,et al. Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood–Brain Barrier Integrity by a Gap Junction-Dependent Mechanism , 2011, The Journal of Neuroscience.
[16] A. Nath,et al. Immune reconstitution inflammatory syndrome and the central nervous system. , 2011, Current opinion in neurology.
[17] J. Clements,et al. Eradication of HIV from the brain: reasons for pause. , 2011, AIDS.
[18] Michael J. Taylor,et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy , 2010, Neurology.
[19] J. Berman,et al. Gap Junctions Mediate Human Immunodeficiency Virus-Bystander Killing in Astrocytes , 2007, The Journal of Neuroscience.
[20] J. Becker,et al. Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.
[21] A. E. Wiencken-barger,et al. A role for Connexin43 during neurodevelopment , 2007, Glia.
[22] G. Fishman,et al. Proliferation of Adult Sertoli Cells Following Conditional Knockout of the Gap Junctional Protein GJA1 (Connexin 43) in Mice1 , 2007, Biology of reproduction.
[23] M. Churchill,et al. Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues , 2006, Journal of NeuroVirology.
[24] P. Simmonds,et al. Influence of HAART on HIV-related CNS disease and neuroinflammation. , 2005, Journal of neuropathology and experimental neurology.
[25] M. Bennett,et al. Role of connexin-based gap junction channels and hemichannels in ischemia-induced cell death in nervous tissue , 2004, Brain Research Reviews.
[26] K. Willecke,et al. Astrocyte cultures from conditional connexin43‐deficient mice , 2004, Glia.
[27] M. Bennett,et al. New roles for astrocytes: Gap junction hemichannels have something to communicate , 2003, Trends in Neurosciences.
[28] E. Dere,et al. Mice with astrocyte‐directed inactivation of connexin43 exhibit increased exploratory behaviour, impaired motor capacities, and changes in brain acetylcholine levels , 2003, The European journal of neuroscience.
[29] M. Bennett,et al. Gap junction hemichannels in astrocytes of the CNS. , 2003, Acta physiologica Scandinavica.
[30] U. Heinemann,et al. Accelerated Hippocampal Spreading Depression and Enhanced Locomotory Activity in Mice with Astrocyte-Directed Inactivation of Connexin43 , 2003, The Journal of Neuroscience.
[31] K. Willecke,et al. hGFAP‐cre transgenic mice for manipulation of glial and neuronal function in vivo , 2001, Genesis.
[32] K. Willecke,et al. Endothelium‐specific replacement of the connexin43 coding region by a lacZ reporter gene , 2001, Genesis.
[33] Anthony S. Fauci,et al. AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.
[34] C A Wiley,et al. HIV mediates a productive infection of the brain. , 1999, AIDS.
[35] M. Garber,et al. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. , 1998, Genes & development.
[36] M. Mattson,et al. Astrocytic Gap Junctional Communication Decreases Neuronal Vulnerability to Oxidative Stress‐Induced Disruption of Ca2+ Homeostasis and Cell Death , 1998, Journal of neurochemistry.
[37] C. Raker,et al. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[39] B L Langille,et al. Cardiac malformation in neonatal mice lacking connexin43. , 1995, Science.
[40] B. Brew,et al. HIV-associated neurocognitive disorder. , 2018, Handbook of clinical neurology.
[41] J. Hervé,et al. Connexin-made channels as pharmacological targets. , 2005, Current pharmaceutical design.
[42] Global AIDS update. , 1992, World health forum.